AR039780A1 - Ligandos receptores de melanocortina - Google Patents
Ligandos receptores de melanocortinaInfo
- Publication number
- AR039780A1 AR039780A1 ARP030101501A ARP030101501A AR039780A1 AR 039780 A1 AR039780 A1 AR 039780A1 AR P030101501 A ARP030101501 A AR P030101501A AR P030101501 A ARP030101501 A AR P030101501A AR 039780 A1 AR039780 A1 AR 039780A1
- Authority
- AR
- Argentina
- Prior art keywords
- aromatic carbocyclic
- rings
- carbocyclic rings
- aromatic
- mixtures
- Prior art date
Links
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
Abstract
Composición que comprende una cantidad eficaz de uno o más ligandos receptores de malanocortina de la fórmula (1) y uno o más excipientes farmacéuticamente aceptables. Se usan para controlar el aumento de peso corporal y otros trastornos como obesidad, anorexia y caquexia. Reivindicación 1: Un compuesto, incluyendo todas las formas enantioméricas y diastereoméricas y las sales farmacéuticamente aceptables de éstas, el compuesto antes mencionado tiene la fórmula (1) en donde R es una unidad de hidrocarburo sustituido o no sustituido que se selecciona del grupo que consiste de: a) anillos carbocíclicos no aromáticos, b) anillos carbocíclicos aromáticos, c) anillos heterocíclicos no aromáticos, d) anillos heterocíclicos aromáticos; W1 es una unidad pendiente que tiene la fórmula (2); R1 se selecciona del grupo que consiste de: i) H, ii) anillos carbocíclicos no aromáticos C3-8, iii) C3-8 anillos carbocíclicos aromáticos C3-8; iv) anillos heterocíclicos no aromáticos C1-7; y v) anillos heterocíclicos aromáticos C3-13; R3a y R3b cada uno independientemente se selecciona del grupo que consiste de: i) H, ii) metilo; y iii) R3a y R3b se pueden tomar juntos para formar una unidad de carbonilo; el índice x tiene el valor de 0 a 10; W2 es una unidad pendiente que tiene la fórmula (3); R2 se selecciona del grupo que consiste de: i) H, ii) anillos carbocíclicos no aromáticos C3-8; iii) anillos carbocíclicos aromáticos C6-14; iv) anillos carbocíclicos no aromáticos C1-7; v) anillos heterocíclicos aromáticos C3-13; vi) -C(Y)R4; vii) -C(Y)2R4; viii) -C(Y)N(R4)2; ix) -C(Y)NR4N(R4)2; x) -CN, xi) -[C(R4)2]C(R4)2; xii) -N(R4)2; xiii) -NR4CN-, xiv) -NR5C(Y)R4; xv) -NR5C(Y)N(R4)2; xvi) -NHN(R4)2; xvii) -NHOR4; xviii) -NO2; xix) -OR4; xx) y mezclas de éstos; Y es -O-, -S-, =O, =S, =NR4, -R4, y mezclas de éstos; R4 es H, alquilo C1-4; -OH, y mezclas de éstos; R5 es H, halógeno, y mezclas de éstos; M es H o un catión formador de sal; R3a y R3b son iguales que lo anterior; el índice v tiene el valor de 0 a 10.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37672702P | 2002-04-30 | 2002-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039780A1 true AR039780A1 (es) | 2005-03-02 |
Family
ID=29401395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101501A AR039780A1 (es) | 2002-04-30 | 2003-04-29 | Ligandos receptores de melanocortina |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20040010010A1 (es) |
| EP (1) | EP1499314A1 (es) |
| JP (1) | JP2005525410A (es) |
| KR (1) | KR20040104671A (es) |
| CN (1) | CN1655785A (es) |
| AR (1) | AR039780A1 (es) |
| AU (1) | AU2003234094B2 (es) |
| BR (1) | BR0309748A (es) |
| CA (1) | CA2483806A1 (es) |
| IL (1) | IL164697A0 (es) |
| MA (1) | MA27593A1 (es) |
| MX (1) | MXPA04010762A (es) |
| NO (1) | NO20045126L (es) |
| PE (1) | PE20040375A1 (es) |
| PL (1) | PL373575A1 (es) |
| RU (1) | RU2004134719A (es) |
| TW (1) | TW200404543A (es) |
| WO (1) | WO2003092690A1 (es) |
| ZA (1) | ZA200408528B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7354923B2 (en) | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| SE0400850D0 (sv) * | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| FR2870243B1 (fr) | 2004-05-11 | 2010-11-19 | Centre Nat Rech Scient | Conjugues tripeptidiques agonistes de la msh |
| FR2870244B1 (fr) * | 2004-05-11 | 2011-01-07 | Centre Nat Rech Scient | Conjugues dipeptidiques antagonistes de l'alpha-msh |
| DE602005018779D1 (de) | 2004-07-19 | 2010-02-25 | Merck & Co Inc | Acylierte piperidinderivative als melanocortin-4-rezeptoragonisten |
| FR2873690B1 (fr) * | 2004-07-29 | 2006-10-13 | Sanofi Synthelabo | Derives d'oxopiperidine, leur preparation et leur application en therapeutique |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| BRPI0616463A2 (pt) | 2005-09-29 | 2011-06-21 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
| US7652024B2 (en) | 2005-10-18 | 2010-01-26 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| WO2007096186A1 (en) * | 2006-02-23 | 2007-08-30 | Santhera Pharmaceuticals (Schweiz) Ag | Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators |
| EP1826201A1 (en) * | 2006-02-23 | 2007-08-29 | Santhera Pharmaceuticals (Schweiz) AG | Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators |
| EP2019100A1 (en) * | 2007-07-19 | 2009-01-28 | Santhera Pharmaceuticals (Schweiz) AG | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| JP5514831B2 (ja) | 2008-11-17 | 2014-06-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療のための置換二環式アミン |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| EP2579873A4 (en) | 2010-06-11 | 2013-11-27 | Merck Sharp & Dohme | NOVEL PROLYLCARBOXYPEPTIDASE HEMMER |
| WO2012100342A1 (en) | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK704488D0 (da) * | 1988-12-19 | 1988-12-19 | Novo Industri As | Nye n-substituerede azaheterocykliske carboxylsyrer |
| US5578593A (en) * | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
| US5494919A (en) * | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5492916A (en) * | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5721251A (en) * | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| US5721250A (en) * | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5783582A (en) * | 1994-07-20 | 1998-07-21 | Merck & Co., Inc. | Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone |
| US5536718A (en) * | 1995-01-17 | 1996-07-16 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| ATE288444T1 (de) * | 1995-05-29 | 2005-02-15 | Pfizer | Dipeptide, die die ausschüttung von wachstumshormonen stimulieren |
| AR004980A1 (es) * | 1995-11-29 | 1999-04-07 | Nihon Nohyaku Co Ltd | Fungicida para la fruta de cultivo, derivado de fenilalanina comprendido como ingrediente activo en el mismo y metodo para controlar enfermedades enplantas aplicando dicho fungicida. |
| GB9612276D0 (en) * | 1996-06-12 | 1996-08-14 | Merck & Co Inc | 4-Spiroindoline piperidines promote release of growth hormone |
| US5804578A (en) * | 1996-04-03 | 1998-09-08 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5877182A (en) * | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| US5965565A (en) * | 1996-12-12 | 1999-10-12 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| US6294534B1 (en) * | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| CA2377369A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| AU1596101A (en) * | 1999-11-12 | 2001-06-06 | Merck & Co., Inc. | Aliphatic amine substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents |
| JP2003528088A (ja) * | 2000-03-23 | 2003-09-24 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
| JP2004506687A (ja) * | 2000-08-23 | 2004-03-04 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
| CA2437594A1 (en) * | 2001-03-02 | 2002-09-12 | Graham S. Poindexter | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| EP1370211A4 (en) * | 2001-03-02 | 2005-02-09 | Bristol Myers Squibb Co | SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP |
-
2003
- 2003-04-09 US US10/410,784 patent/US20040010010A1/en not_active Abandoned
- 2003-04-11 PE PE2003000371A patent/PE20040375A1/es not_active Application Discontinuation
- 2003-04-16 RU RU2004134719/04A patent/RU2004134719A/ru not_active Application Discontinuation
- 2003-04-16 WO PCT/US2003/011537 patent/WO2003092690A1/en not_active Ceased
- 2003-04-16 KR KR10-2004-7017451A patent/KR20040104671A/ko not_active Ceased
- 2003-04-16 PL PL03373575A patent/PL373575A1/xx not_active Application Discontinuation
- 2003-04-16 CA CA002483806A patent/CA2483806A1/en not_active Abandoned
- 2003-04-16 TW TW092108827A patent/TW200404543A/zh unknown
- 2003-04-16 AU AU2003234094A patent/AU2003234094B2/en not_active Ceased
- 2003-04-16 JP JP2004500874A patent/JP2005525410A/ja not_active Withdrawn
- 2003-04-16 MX MXPA04010762A patent/MXPA04010762A/es unknown
- 2003-04-16 BR BR0309748-0A patent/BR0309748A/pt not_active IP Right Cessation
- 2003-04-16 CN CNA038122235A patent/CN1655785A/zh active Pending
- 2003-04-16 EP EP03728400A patent/EP1499314A1/en not_active Withdrawn
- 2003-04-29 AR ARP030101501A patent/AR039780A1/es not_active Application Discontinuation
-
2004
- 2004-10-19 IL IL16469704A patent/IL164697A0/xx unknown
- 2004-10-21 ZA ZA200408528A patent/ZA200408528B/en unknown
- 2004-10-27 MA MA27917A patent/MA27593A1/fr unknown
- 2004-11-24 NO NO20045126A patent/NO20045126L/no not_active Application Discontinuation
-
2005
- 2005-06-30 US US11/172,059 patent/US20050239835A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040010010A1 (en) | 2004-01-15 |
| KR20040104671A (ko) | 2004-12-10 |
| CN1655785A (zh) | 2005-08-17 |
| ZA200408528B (en) | 2005-07-07 |
| MA27593A1 (fr) | 2005-11-01 |
| BR0309748A (pt) | 2005-02-15 |
| AU2003234094B2 (en) | 2006-03-09 |
| AU2003234094A1 (en) | 2003-11-17 |
| IL164697A0 (en) | 2005-12-18 |
| WO2003092690A1 (en) | 2003-11-13 |
| NO20045126L (no) | 2005-01-21 |
| PL373575A1 (en) | 2005-09-05 |
| TW200404543A (en) | 2004-04-01 |
| JP2005525410A (ja) | 2005-08-25 |
| MXPA04010762A (es) | 2005-03-07 |
| RU2004134719A (ru) | 2005-06-27 |
| CA2483806A1 (en) | 2003-11-13 |
| US20050239835A1 (en) | 2005-10-27 |
| EP1499314A1 (en) | 2005-01-26 |
| PE20040375A1 (es) | 2004-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039780A1 (es) | Ligandos receptores de melanocortina | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR043014A1 (es) | Amino-1,3,5-triazinas n-sustituidas con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas, y su uso como herbicidas y reguladores del crecimiento de las plantas | |
| PE20191532A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| AR058618A1 (es) | "( indazol -5- il) - pirazinas y (1,3- dihidro- indol-2- ona) - pirazinas para el tratamiento de enfermedades y afecciones mediadas por rho quinasa | |
| AR058362A1 (es) | Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos | |
| AR061829A1 (es) | Ciclobuten-1, 2-dionas 3,4-di sustituidas como ligandos de receptores de quimiocinas cxc | |
| AR077505A1 (es) | Compuestos de piridina y sus usos | |
| AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
| AR033516A1 (es) | Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo, su uso en la fabricacion de medicamentos y composiciones que los contienen | |
| AR051735A1 (es) | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. | |
| AR088919A2 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y uso | |
| AR022303A1 (es) | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion | |
| AR031680A1 (es) | Utilizacion de acrilamidas de quinuclidina para la preparacion de medicamentos, compuestos y composicion farmaceutica | |
| AR070540A1 (es) | Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer. | |
| AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
| AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
| AR065464A1 (es) | Derivados de nicotinamida. composiciones farmaceuticas | |
| AR087515A1 (es) | Compuestos de n-tio-antranilamida y sus usos como plaguicidas | |
| PE20242225A1 (es) | Degradadores de dedos de zinc de la familia ikaros y usos de estos | |
| AR045999A1 (es) | Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo | |
| AR111176A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos | |
| AR042002A1 (es) | Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. | |
| GT200000049A (es) | Compuestos quimicos. | |
| AR070930A1 (es) | Derivados de pirrolidinilo y tiofeno, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de enfermedades asociadas con inhibidores de reabsorcion de monoaminas,tales como trastornos depresivos y ansioliticos, entre otros. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |